Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Biocept, Inc. logo — Helping physicians improve outcomes for metastatic cancer pa...

Biocept, Inc.

Helping physicians improve outcomes for metastatic cancer patients by delivering advanced diagnostic testing solutions.

Founded 1993 United States San Diego, United States 49 employees Post-IPO Equity Total: $48.20M Biotechnology, Health Care

General Information

Company Name Biocept, Inc.
Founded Year 1993
Location United States San Diego, United States
Founders / Decision Makers
Team member
Employees 49
Industries Biotechnology, Health Care
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Biocept, Inc. . To contact Biocept, Inc. , visit biocept.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Biocept, Inc. compare?

A PDF of Biocept, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Biocept, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Biocept, Inc.

Biocept, Inc. is a biotechnology company based in the United States, founded in 1993 with a focus on providing advanced diagnostic testing solutions for metastatic cancer patients. Their CNSide™ assay offers enhanced detection and analysis of tumor cells and cell-free DNA from cerebrospinal fluid, aiding in the evaluation of treatment response and characterization of genetic changes associated with therapy resistance. Their CLIA-certified and CAP-accredited laboratory is dedicated to helping oncologists manage the complexities of cancer, addressing critical questions related to treatment and response trends. The company recently received a $5.00 million post-IPO equity investment on May 24, 2023. This investment will likely support the expansion of their diagnostic testing solutions and contribute to their ongoing efforts to improve outcomes for cancer patients. Biocept's dedication to improving cancer care and the provision of RT-PCR based COVID-19 testing to support public health efforts demonstrates their commitment to impacting healthcare on a broader scale. With a focus on biotechnology and healthcare, Biocept, Inc. exemplifies a forward-thinking approach to diagnostic solutions in the field of oncology.

Business keywords: clinical laboratory tests, oncology testing, liquid biopsy, metastatic cancer, diagnostic assays, cell separation technology, cancer diagnostics, clinical services, molecular testing, COVID-19 testing, genetic markers, personalized medicine, rare cell analysis, cerebrospinal fluid (CSF) testing

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $5.00M -
24 May 2023
Post IPO Equity $14.80M -
30 Jan 2018
Post IPO Equity $9.30M 2
ROTH Capital Partners
ROTH Capital Partners, Chardan Capital
28 Mar 2017
Debt Financing $1.20M -
16 Feb 2011
Series B $2.30M -
12 Aug 2010
Series A $3.60M -
29 Mar 2010
Venture Round $10.00M 1
Needham Capital Partners
Needham Capital Partners
23 Jun 2006
Venture Round $2.00M -
01 Oct 2002

Biocept, Inc. Alternatives & Competitors

View All Alternatives
Biocept, Inc. vs
3DMedcare
3DMedcare United States

We are dedicated to providing precision diagnosis solutions to any patient, anytime, anywhere.

Series D
113 employees
Biopharma, Biotechnology
Compare Biocept, Inc. vs 3DMedcare
Biocept, Inc. vs
Metamark Genetics
Metamark Genetics United States

Metamark - A leader in comprehensive urology cancer care

Growth
23 employees
Biotechnology, Health Care
Compare Biocept, Inc. vs Metamark Genetics
Biocept, Inc. vs
Elphogene, s.r.o.
Elphogene, s.r.o. Czech Republic

Společnost poskytuje unikátní molekulární test oncoMonitor™ pro sledování průběhu a léčby nádorového...

Seed
6 employees
Biotechnology, Health Care
Also compare with: Biocept, Inc. vs mdxhealth mdxhealth View all alternatives

FAQ About Biocept, Inc.

Helping physicians improve outcomes for metastatic cancer patients by delivering advanced diagnostic testing solutions.
Biocept, Inc. was founded in 1993.
Biocept, Inc. is headquartered in San Diego, United States.
Biocept, Inc. operates in Biotechnology and Health Care. Its work centres on clinical laboratory tests, oncology testing, liquid biopsy and metastatic cancer.
Biocept, Inc. has approximately 49 employees.
Biocept, Inc. has completed 8 funding rounds, raising a total of $48.20M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Biocept, Inc. include 3DMedcare, Metamark Genetics, Elphogene, s.r.o., 广州嘉检医学检测有限公司, Biodesix, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Biocept, Inc. and 3DMedcare are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Biocept, Inc. , https://bouncewatch.com/company/biocept-inc, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout